1/23/2020 7:13:48 AM
Altimmune Announces Positive Results For ALT-702 In Preclinical Model Of Colorectal Cancer
9/9/2019 7:09:54 AM
Altimmune Appoints Scott Harris As Chief Medical Officer
7/15/2019 7:07:58 AM
Altimmune Announces Closing Of Acquisition Of Spitfire Pharma
7/9/2019 7:19:11 AM
Altimmune To Acquire Spitfire Pharma
7/9/2019 7:05:14 AM
Altimmune Agrees To Acquire Spitfire Pharma; Transaction To Close During July
6/10/2019 8:10:13 AM
Altimmune Reports Pre-IND Meeting For HepTcell; Phase 2 Trial To Start In 2020
6/5/2019 8:12:57 AM
Altimmune Receives Addl Patent Protection For Its HepTcell And ALT-702 Programs
3/19/2019 7:09:04 AM
Altimmune Announces Positive Results From NasoVAX Extension Study
1/29/2019 8:08:42 AM
Altimmune Announces Presentation Of HepTcell Phase 1 Results At International Liver Congress™ In Vienna, Austria
12/13/2018 7:04:03 AM
Altimmune Announces Clinical Program Updates And Plans For Pipeline Expansion
11/27/2018 9:04:00 AM
Altimmune Appoints Vipin Garg As Its President And CEO Succeeding Bill Enright
10/8/2018 9:05:02 AM
Altimmune Plans $25 Mln Registered Direct Offering
9/24/2018 9:10:40 AM
Altimmune Announces $4.9 Mln Registered Direct Offering Of Common Stock